Literature DB >> 15834429

PI 3-kinase p110beta: a new target for antithrombotic therapy.

Shaun P Jackson1, Simone M Schoenwaelder, Isaac Goncalves, Warwick S Nesbitt, Cindy L Yap, Christine E Wright, Vijaya Kenche, Karen E Anderson, Sacha M Dopheide, Yuping Yuan, Sharelle A Sturgeon, Hishani Prabaharan, Philip E Thompson, Gregg D Smith, Peter R Shepherd, Nathalie Daniele, Suhasini Kulkarni, Belinda Abbott, Dilek Saylik, Catherine Jones, Lucy Lu, Simon Giuliano, Sascha C Hughan, James A Angus, Alan D Robertson, Hatem H Salem.   

Abstract

Platelet activation at sites of vascular injury is essential for the arrest of bleeding; however, excessive platelet accumulation at regions of atherosclerotic plaque rupture can result in the development of arterial thrombi, precipitating diseases such as acute myocardial infarction and ischemic stroke. Rheological disturbances (high shear stress) have an important role in promoting arterial thrombosis by enhancing the adhesive and signaling function of platelet integrin alpha(IIb)beta(3) (GPIIb-IIIa). In this study we have defined a key role for the Type Ia phosphoinositide 3-kinase (PI3K) p110beta isoform in regulating the formation and stability of integrin alpha(IIb)beta(3) adhesion bonds, necessary for shear activation of platelets. Isoform-selective PI3K p110beta inhibitors have been developed which prevent formation of stable integrin alpha(IIb)beta(3) adhesion contacts, leading to defective platelet thrombus formation. In vivo, these inhibitors eliminate occlusive thrombus formation but do not prolong bleeding time. These studies define PI3K p110beta as an important new target for antithrombotic therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834429     DOI: 10.1038/nm1232

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  189 in total

Review 1.  Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

Authors:  Qi-Wen Fan; William A Weiss
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

2.  Development of a peptide-drug conjugate for prostate cancer therapy.

Authors:  Wanyi Tai; Ravi S Shukla; Bin Qin; Benyi Li; Kun Cheng
Journal:  Mol Pharm       Date:  2011-05-03       Impact factor: 4.939

3.  Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110β isoform of phosphatidylinositol 3-kinase.

Authors:  Sameer Mohammad; Lavoisier S Ramos; Jochen Buck; Lonny R Levin; Francesco Rubino; Timothy E McGraw
Journal:  J Biol Chem       Date:  2011-10-25       Impact factor: 5.157

Review 4.  P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells.

Authors:  Christian Gachet
Journal:  Purinergic Signal       Date:  2012-04-11       Impact factor: 3.765

Review 5.  ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.

Authors:  De-xin Kong; Takao Yamori
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

6.  Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair.

Authors:  Amit Kumar; Oscar Fernandez-Capetillo; Oscar Fernadez-Capetillo; Ana C Carrera
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

7.  Activity of any class IA PI3K isoform can sustain cell proliferation and survival.

Authors:  Lazaros C Foukas; Inma M Berenjeno; Alexander Gray; Asim Khwaja; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

8.  Phosphoinositide 3-kinase gamma regulates airway smooth muscle contraction by modulating calcium oscillations.

Authors:  Haihong Jiang; Peter W Abel; Myron L Toews; Caishu Deng; Thomas B Casale; Yan Xie; Yaping Tu
Journal:  J Pharmacol Exp Ther       Date:  2010-05-25       Impact factor: 4.030

Review 9.  PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Authors:  Vera P Krymskaya; Elena A Goncharova
Journal:  Cell Cycle       Date:  2009-02-06       Impact factor: 4.534

10.  Hematopoietic lineage cell specific protein 1 (HS1) is a functionally important signaling molecule in platelet activation.

Authors:  Bryan N Kahner; Robert T Dorsam; Sripal R Mada; Soochong Kim; Timothy J Stalker; Lawrence F Brass; James L Daniel; Daisuke Kitamura; Satya P Kunapuli
Journal:  Blood       Date:  2007-06-19       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.